Chongqing Jiheng Pharmaceutical Co., Ltd. (SHE:002742)
China · Delayed Price · Currency is CNY 3.520
-0.040 (-1.12%)
Nov 13, 2026, 3:04 PM CST
SHE:002742 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 479.89 | 882.77 | 1,169 | 2,004 | 2,055 | 2,450 |
Other Revenue | 17.08 | 17.08 | 26.22 | 25.85 | 22.13 | 38.69 |
| 496.97 | 899.85 | 1,196 | 2,030 | 2,077 | 2,489 | |
Revenue Growth | -47.51% | -24.74% | -41.10% | -2.25% | -16.56% | -2.37% |
Cost of Revenue | 460.69 | 769.89 | 998.94 | 1,650 | 1,769 | 2,084 |
Gross Profit | 36.28 | 129.95 | 196.78 | 380.04 | 307.68 | 405.41 |
Selling, General & Admin | 106.33 | 211 | 241.23 | 271.58 | 242.93 | 286.29 |
Research & Development | 12.86 | 17.88 | 20.87 | 17.37 | 14.88 | 27.5 |
Other Operating Expenses | 11.47 | 16.14 | 17.08 | 14.9 | 17.11 | 19.57 |
Operating Expenses | 117.65 | 235.25 | 327.47 | 349.32 | 309.49 | 450.81 |
Operating Income | -81.37 | -105.3 | -130.69 | 30.72 | -1.81 | -45.39 |
Interest Expense | -79.14 | -201.44 | -204.97 | -161.34 | -157.58 | -161.03 |
Interest & Investment Income | 48.62 | 48.7 | 126.78 | 0.96 | 2 | 8.32 |
Currency Exchange Gain (Loss) | 0.22 | 0.22 | 4.29 | 0 | 1.66 | -9.04 |
Other Non Operating Income (Expenses) | -5.49 | -10.08 | -3.09 | -7.88 | -14.68 | -6.15 |
EBT Excluding Unusual Items | -117.15 | -267.89 | -207.67 | -137.53 | -170.42 | -213.29 |
Impairment of Goodwill | -126.78 | -126.78 | -181.77 | - | - | - |
Gain (Loss) on Sale of Assets | -1.26 | -0.14 | 21.07 | 0.81 | 21.01 | 14.81 |
Asset Writedown | -32.24 | -32.24 | -205.1 | -143.51 | -64.53 | -124.39 |
Other Unusual Items | -11.96 | -9.65 | -55.47 | -47.72 | -26.39 | -19.69 |
Pretax Income | -290.65 | -436.7 | -628.95 | -327.94 | -240.33 | -342.55 |
Income Tax Expense | 16.07 | 22.08 | 20.8 | 81.37 | 51.26 | 18.28 |
Earnings From Continuing Operations | -306.72 | -458.79 | -649.75 | -409.31 | -291.59 | -360.84 |
Minority Interest in Earnings | 38.16 | 39.11 | -0.38 | -42.73 | -26.29 | 27.4 |
Net Income | -268.56 | -419.68 | -650.13 | -452.05 | -317.88 | -333.44 |
Net Income to Common | -268.56 | -419.68 | -650.13 | -452.05 | -317.88 | -333.44 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 877 | 688 | 684 | 431 | 430 | 432 |
Shares Outstanding (Diluted) | 877 | 688 | 684 | 431 | 430 | 432 |
Shares Change | 28.21% | 0.53% | 58.96% | 0.22% | -0.57% | 0.01% |
EPS (Basic) | -0.31 | -0.61 | -0.95 | -1.05 | -0.74 | -0.77 |
EPS (Diluted) | -0.31 | -0.61 | -0.95 | -1.05 | -0.74 | -0.77 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -114.99 | -35.29 | -105.43 | -98.07 | 4.87 | 41.03 |
Free Cash Flow Per Share | -0.13 | -0.05 | -0.15 | -0.23 | 0.01 | 0.10 |
Gross Margin | 7.30% | 14.44% | 16.46% | 18.72% | 14.81% | 16.29% |
Operating Margin | -16.37% | -11.70% | -10.93% | 1.51% | -0.09% | -1.82% |
Profit Margin | -54.04% | -46.64% | -54.37% | -22.27% | -15.30% | -13.40% |
Free Cash Flow Margin | -23.14% | -3.92% | -8.82% | -4.83% | 0.24% | 1.65% |
EBITDA | -4.22 | -12.38 | -16.76 | 157.21 | 130.33 | 103.84 |
EBITDA Margin | -0.85% | -1.38% | -1.40% | 7.74% | 6.28% | 4.17% |
D&A For EBITDA | 77.15 | 92.91 | 113.93 | 126.49 | 132.15 | 149.23 |
EBIT | -81.37 | -105.3 | -130.69 | 30.72 | -1.81 | -45.39 |
EBIT Margin | -16.37% | -11.70% | -10.93% | 1.51% | -0.09% | -1.82% |
Revenue as Reported | 162.58 | 899.85 | 1,196 | 2,030 | 2,077 | 2,489 |